FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2048005105> ?p ?o ?g. }

• W2048005105 endingPage "957" @default.
• W2048005105 startingPage "951" @default.
• W2048005105 abstract "Autologous stem cell transplantation (ASCT) prolongs survival in patients with relapsed follicular lymphoma. ASCT is usually not curative, however. Myeloablative allogeneic transplantation has produced long-term survival at a cost of significant transplantation-related mortality (TRM), whereas reduced-intensity transplantation entails less TRM but has a higher relapse rate. We thus initiated a protocol consisting of ASCT followed by nonmyeloablative allogeneic transplantation (NMT) for relapsed follicular lymphoma to mimic myeloablative allogeneic transplantation without the associated toxicity. The NMT was non–T cell-depleted, and all donors were HLA-identical siblings. We report results in 27 patients with a median age of 49 years (range, 34-65 years). Five patients demonstrated histological progression toward an aggressive lymphoma. The patients had received a median of 3 lines of previous therapy. Disease status before ASCT included 8 patients in complete remission, 14 in partial remission, and 5 refractory. Five patients developed grade II-IV acute graft-versus-host disease, and 20 patients developed chronic graft-versus-host disease requiring systemic therapy. With a median follow-up of 39 months after NMT, overall survival and progression-free survival were 96% at 3 years. We conclude that the combined ASCT-NMT strategy appears to be safe, with excellent progression-free survival even in refractory and transformed cases. This novel approach warrants further investigation in larger prospective studies. Autologous stem cell transplantation (ASCT) prolongs survival in patients with relapsed follicular lymphoma. ASCT is usually not curative, however. Myeloablative allogeneic transplantation has produced long-term survival at a cost of significant transplantation-related mortality (TRM), whereas reduced-intensity transplantation entails less TRM but has a higher relapse rate. We thus initiated a protocol consisting of ASCT followed by nonmyeloablative allogeneic transplantation (NMT) for relapsed follicular lymphoma to mimic myeloablative allogeneic transplantation without the associated toxicity. The NMT was non–T cell-depleted, and all donors were HLA-identical siblings. We report results in 27 patients with a median age of 49 years (range, 34-65 years). Five patients demonstrated histological progression toward an aggressive lymphoma. The patients had received a median of 3 lines of previous therapy. Disease status before ASCT included 8 patients in complete remission, 14 in partial remission, and 5 refractory. Five patients developed grade II-IV acute graft-versus-host disease, and 20 patients developed chronic graft-versus-host disease requiring systemic therapy. With a median follow-up of 39 months after NMT, overall survival and progression-free survival were 96% at 3 years. We conclude that the combined ASCT-NMT strategy appears to be safe, with excellent progression-free survival even in refractory and transformed cases. This novel approach warrants further investigation in larger prospective studies." @default.
• W2048005105 created "2016-06-24" @default.
• W2048005105 creator A5013013635 @default.
• W2048005105 creator A5020893651 @default.
• W2048005105 creator A5027155042 @default.
• W2048005105 creator A5038131650 @default.
• W2048005105 creator A5043492753 @default.
• W2048005105 creator A5050193702 @default.
• W2048005105 creator A5051289075 @default.
• W2048005105 creator A5051537994 @default.
• W2048005105 date "2012-06-01" @default.
• W2048005105 modified "2023-10-02" @default.
• W2048005105 title "Tandem Autologous–Allogeneic Nonmyeloablative Sibling Transplantation in Relapsed Follicular Lymphoma Leads to Impressive Progression-Free Survival with Minimal Toxicity" @default.
• W2048005105 cites W1504115866 @default.
• W2048005105 cites W1834370350 @default.
• W2048005105 cites W1883328448 @default.
• W2048005105 cites W1912693401 @default.
• W2048005105 cites W1937538988 @default.
• W2048005105 cites W1972430398 @default.
• W2048005105 cites W1986483184 @default.
• W2048005105 cites W2000686577 @default.
• W2048005105 cites W2001851267 @default.
• W2048005105 cites W2005087893 @default.
• W2048005105 cites W2019131761 @default.
• W2048005105 cites W2038290388 @default.
• W2048005105 cites W2039845134 @default.
• W2048005105 cites W2046834426 @default.
• W2048005105 cites W2050171635 @default.
• W2048005105 cites W2055468114 @default.
• W2048005105 cites W2057456103 @default.
• W2048005105 cites W2058887761 @default.
• W2048005105 cites W2060136712 @default.
• W2048005105 cites W2067670674 @default.
• W2048005105 cites W2080607847 @default.
• W2048005105 cites W2085947607 @default.
• W2048005105 cites W2086429132 @default.
• W2048005105 cites W2097470232 @default.
• W2048005105 cites W2098901377 @default.
• W2048005105 cites W2099156781 @default.
• W2048005105 cites W2101019586 @default.
• W2048005105 cites W2104795464 @default.
• W2048005105 cites W2117964879 @default.
• W2048005105 cites W2123477526 @default.
• W2048005105 cites W2126439311 @default.
• W2048005105 cites W2129128251 @default.
• W2048005105 cites W2131140606 @default.
• W2048005105 cites W2132589242 @default.
• W2048005105 cites W2150748222 @default.
• W2048005105 cites W2153859516 @default.
• W2048005105 cites W2158424965 @default.
• W2048005105 cites W2162489923 @default.
• W2048005105 cites W2259204434 @default.
• W2048005105 cites W2335097692 @default.
• W2048005105 cites W2395585278 @default.
• W2048005105 cites W2618073389 @default.
• W2048005105 cites W4246085869 @default.
• W2048005105 doi "https://doi.org/10.1016/j.bbmt.2011.11.028" @default.
• W2048005105 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22155507" @default.
• W2048005105 hasPublicationYear "2012" @default.
• W2048005105 type Work @default.
• W2048005105 sameAs 2048005105 @default.
• W2048005105 citedByCount "20" @default.
• W2048005105 countsByYear W20480051052012 @default.
• W2048005105 countsByYear W20480051052013 @default.
• W2048005105 countsByYear W20480051052014 @default.
• W2048005105 countsByYear W20480051052015 @default.
• W2048005105 countsByYear W20480051052016 @default.
• W2048005105 crossrefType "journal-article" @default.
• W2048005105 hasAuthorship W2048005105A5013013635 @default.
• W2048005105 hasAuthorship W2048005105A5020893651 @default.
• W2048005105 hasAuthorship W2048005105A5027155042 @default.
• W2048005105 hasAuthorship W2048005105A5038131650 @default.
• W2048005105 hasAuthorship W2048005105A5043492753 @default.
• W2048005105 hasAuthorship W2048005105A5050193702 @default.
• W2048005105 hasAuthorship W2048005105A5051289075 @default.
• W2048005105 hasAuthorship W2048005105A5051537994 @default.
• W2048005105 hasBestOaLocation W20480051051 @default.
• W2048005105 hasConcept C126322002 @default.
• W2048005105 hasConcept C141071460 @default.
• W2048005105 hasConcept C143998085 @default.
• W2048005105 hasConcept C2776283816 @default.
• W2048005105 hasConcept C2776694085 @default.
• W2048005105 hasConcept C2777058707 @default.
• W2048005105 hasConcept C2779050716 @default.
• W2048005105 hasConcept C2779338263 @default.
• W2048005105 hasConcept C2780739268 @default.
• W2048005105 hasConcept C2911091166 @default.
• W2048005105 hasConcept C71924100 @default.
• W2048005105 hasConceptScore W2048005105C126322002 @default.
• W2048005105 hasConceptScore W2048005105C141071460 @default.
• W2048005105 hasConceptScore W2048005105C143998085 @default.
• W2048005105 hasConceptScore W2048005105C2776283816 @default.
• W2048005105 hasConceptScore W2048005105C2776694085 @default.
• W2048005105 hasConceptScore W2048005105C2777058707 @default.
• W2048005105 hasConceptScore W2048005105C2779050716 @default.
• W2048005105 hasConceptScore W2048005105C2779338263 @default.
• W2048005105 hasConceptScore W2048005105C2780739268 @default.
• W2048005105 hasConceptScore W2048005105C2911091166 @default.

• next